Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued
Reference number: GID-TA10596
The Department for Health and Social Care has asked NICE to conduct an appraisal of tralokinumab for treating moderate to severe atopic dermatitis.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2021. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.